

Immunity in amyotrophic lateral sclerosis: blurred lines and inefficient immune responses

Brain Communications

2, fcaa124

DOI: [10.1093/braincomms/fcaa124](https://doi.org/10.1093/braincomms/fcaa124)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Microbiota-Host Immunity Communication in Neurodegenerative Disorders: Bioengineering Challenges for In Vitro Modeling. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002043.	7.6	18
3	Some CSF Kynurenine Pathway Intermediates Associated with Disease Evolution in Amyotrophic Lateral Sclerosis. <i>Biomolecules</i> , 2021, 11, 691.	4.0	8
4	Aberrant NLRP3 Inflammasome Activation Ignites the Fire of Inflammation in Neuromuscular Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6068.	4.1	5
5	The Gut Microbiota-Immunity Axis in ALS: A Role in Deciphering Disease Heterogeneity?. <i>Biomedicines</i> , 2021, 9, 753.	3.2	25
6	How Inflammation Pathways Contribute to Cell Death in Neuro-Muscular Disorders. <i>Biomolecules</i> , 2021, 11, 1109.	4.0	7
7	Gastrointestinal Status and Microbiota Shaping in Amyotrophic Lateral Sclerosis: A New Frontier for Targeting?. , 0, , 141-158.		2
8	Interleukin-17 and Th17 Lymphocytes Directly Impair Motoneuron Survival of Wildtype and FUS-ALS Mutant Human iPSCs. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8042.	4.1	19
9	Interplay between immunity and amyotrophic lateral sclerosis: Clinical impact. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 127, 958-978.	6.1	22
10	Imaging immunological processes from blood to brain in amyotrophic lateral sclerosis. <i>Clinical and Experimental Immunology</i> , 2021, 206, 301-313.	2.6	5
11	Passive Transfer of Blood Sera from ALS Patients with Identified Mutations Results in Elevated Motoneuronal Calcium Level and Loss of Motor Neurons in the Spinal Cord of Mice. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9994.	4.1	4
12	Study protocol on the safety and feasibility of a normocaloric ketogenic diet in people with amyotrophic lateral sclerosis. <i>Nutrition</i> , 2022, 94, 111525.	2.4	7
13	Immunomodulation induced by central nervous system-related peptides as a therapeutic strategy for neurodegenerative disorders. <i>Pharmacology Research and Perspectives</i> , 2021, 9, e00795.	2.4	6
14	Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. <i>Science Translational Medicine</i> , 2022, 14, eabj0264.	12.4	38
15	HPLC-MS/MS Oxylipin Analysis of Plasma from Amyotrophic Lateral Sclerosis Patients. <i>Biomedicines</i> , 2022, 10, 674.	3.2	11
16	Therapeutic Approaches to Amyotrophic Lateral Sclerosis from the Lab to the Clinic. <i>Current Drug Metabolism</i> , 2022, 23, 200-222.	1.2	4
17	Quantum Biology Research Meets Pathophysiology and Therapeutic Mechanisms: A Biomedical Perspective. <i>Quantum Reports</i> , 2022, 4, 148-172.	1.3	6
18	Superoxide Dismutase-1 Intracellular Content in T Lymphocytes Associates with Increased Regulatory T Cell Level in Multiple Sclerosis Subjects Undergoing Immune-Modulating Treatment. <i>Antioxidants</i> , 2021, 10, 1940.	5.1	4
19	Contingent intramuscular boosting of P2XR7 axis improves motor function in transgenic ALS mice. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 7.	5.4	5

#	ARTICLE	IF	CITATIONS
20	Adenosine deaminase, not immune to a mechanistic rethink in central nervous system disorders?. <i>Histology and Histopathology</i> , 2021, , 18404.	0.7	2
21	Boosting the peripheral immune response in the skeletal muscles improved motor function in ALS transgenic mice. <i>Molecular Therapy</i> , 2022, 30, 2760-2784.	8.2	9
22	Genetic Variability of Inflammation and Oxidative Stress Genes Affects Onset, Progression of the Disease and Survival of Patients with Amyotrophic Lateral Sclerosis. <i>Genes</i> , 2022, 13, 757.	2.4	9
24	Optineurin Deficiency and Insufficiency Lead to Higher Microglial TDP-43 Protein Levels. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6829.	4.1	6
25	Blocking immune cell infiltration of the central nervous system to tame Neuroinflammation in Amyotrophic lateral sclerosis. <i>Brain, Behavior, and Immunity</i> , 2022, 105, 1-14.	4.1	19
26	Taking Advantages of Blood–Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?. <i>Journal of Personalized Medicine</i> , 2022, 12, 1071.	2.5	9
27	Inflammatory mediators, lipoproteins and apolipoproteins in early diagnosis of amyotrophic lateral sclerosis. <i>SLAS Technology</i> , 2022, , .	1.9	0
28	Correlation between Retinal Vascularization and Disease Aggressiveness in Amyotrophic Lateral Sclerosis. <i>Biomedicines</i> , 2022, 10, 2390.	3.2	5
29	Hemizygous Granzyme A Mice Expressing the hSOD1G93A Transgene Show Slightly Extended Lifespan. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13554.	4.1	2
30	The Cellular and Molecular Signature of ALS in Muscle. <i>Journal of Personalized Medicine</i> , 2022, 12, 1868.	2.5	7
31	Ageing-Induced Decline in Primary Myeloid Cell Phagocytosis Is Unaffected by Optineurin Insufficiency. <i>Biology</i> , 2023, 12, 240.	2.8	4
32	Distinct Plasma Immune Profile in ALS Implicates sTNFR-II in pAMPK/Leptin Homeostasis. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5065.	4.1	5
34	Cause or consequence? The role of IL-1 family cytokines and receptors in neuroinflammatory and neurodegenerative diseases. <i>Frontiers in Immunology</i> , 0, 14, .	4.8	2
35	Exploring the Potential Utility of Psychedelic Therapy for Patients With Amyotrophic Lateral Sclerosis. <i>Journal of Palliative Medicine</i> , 0, , .	1.1	0
36	Emerging Trends in the Field of Inflammation and Proteinopathy in ALS/FTD Spectrum Disorder. <i>Biomedicines</i> , 2023, 11, 1599.	3.2	7
37	Levamisole derivatives as immune modulators for the treatment of amyotrophic lateral sclerosis (ALS). <i>Future Medicinal Chemistry</i> , 2023, 15, 651-659.	2.3	0
38	Muscle fatigue and exercise-related biomarkers in amyotrophic lateral sclerosis. , 0, , 164-176.		0
39	Role of neuroinflammation in neurodegeneration development. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	17.1	62

#	ARTICLE	IF	CITATIONS
40	A Step in the ALS Direction: Lessons from the Purinome. , 2023, , 223-258.		0
41	Neuroimmune characterization of optineurin insufficiency mouse model during ageing. Scientific Reports, 2023, 13, .	3.3	1
42	Neuroinflammatory Pathways in the ALS-FTD Continuum: A Focus on Genetic Variants. Genes, 2023, 14, 1658.	2.4	5
43	Causal ALS genes impact the MHC class II antigen presentation pathway. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	7.1	1
44	Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders. Biomedicines, 2023, 11, 2793.	3.2	2
45	Urinary biomarkers for amyotrophic lateral sclerosis: candidates, opportunities and considerations. Brain Communications, 0, , .	3.3	0
46	Theme 06 - Tissue Biomarkers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 161-172.	1.7	0
47	Mobilization of the innate immune response by a specific immunostimulant Î²-glucan confers resistance to chronic stress-induced depression-like behavior by preventing neuroinflammatory responses. International Immunopharmacology, 2024, 127, 111405.	3.8	0
48	CD4 T-cell aging exacerbates neuroinflammation in a late-onset mouse model of amyotrophic lateral sclerosis. Journal of Neuroinflammation, 2024, 21, .	7.2	0
49	Reduction of inflammation and mitochondrial degeneration in mutant SOD1 mice through inhibition of voltage-gated potassium channel Kv1.3. Frontiers in Molecular Neuroscience, 0, 16, .	2.9	0
50	The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology. Progress in Neurobiology, 2024, 235, 102587.	5.7	0
51	Crosstalk between Oxidative Stress and Inflammation Caused by Noise and Air Pollutionâ€”Implications for Neurodegenerative Diseases. Antioxidants, 2024, 13, 266.	5.1	0
52	Dual effects of <sc>TGF</sc>â€² inhibitor in <sc>ALS</sc> â€”inhibit contracture and neurodegeneration. Journal of Neurochemistry, 0, , .	3.9	0
53	Two Cases of Sporadic Amyotrophic Lateral Sclerosis With Contrasting Clinical Phenotypes: Genetic Insights. Cureus, 2024, , .	0.5	0